首页> 外文期刊>Alzheimer s Research & Therapy >Imago Mundi , Imago AD, Imago ADNI
【24h】

Imago Mundi , Imago AD, Imago ADNI

机译:Imago Mundi,Imago AD,Imago ADNI

获取原文
       

摘要

Since the launch in 2003 of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the USA, ever growing, similarly oriented consortia have been organized and assembled around the world. The various accomplishments of ADNI have contributed substantially to a better understanding of the underlying physiopathology of aging and Alzheimer’s disease (AD). These accomplishments are basically predicated in the trinity of multimodality, standardization and sharing. This multimodality approach can now better identify those subjects with AD-specific traits that are more likely to present cognitive decline in the near future and that might represent the best candidates for smaller but more efficient therapeutic trials - trials that, through gained and shared knowledge, can be more focused on a specific target or a specific stage of the disease process. In summary, data generated from ADNI have helped elucidate some of the pathophysiological mechanisms underpinning aging and AD pathology, while contributing to the international effort in setting the groundwork for biomarker discovery and establishing standards for early diagnosis of AD.
机译:自2003年在美国发起“阿尔茨海默氏病神经成像计划(ADNI)”以来,在世界范围内组织并聚集了类似方向的财团。 ADNI的各种成就为更好地理解衰老和阿尔茨海默氏病(AD)的潜在生理病理学做出了巨大贡献。这些成就基本上以多模式,标准化和共享的三位一体为基础。现在,这种多模式方法可以更好地识别那些具有AD特质的受试者,这些受试者在不久的将来更有可能出现认知能力下降,并且可能代表较小但更有效的治疗试验的最佳候选人-通过获得和共享的知识进行的试验,可以更专注于疾病过程的特定目标或特定阶段。总之,从ADNI产生的数据已帮助阐明了支持衰老和AD病理的某些病理生理机制,同时为国际上为建立生物标记物发现基础和建立AD早期诊断标准的努力做出了贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号